NCT03318159View on ClinicalTrials.gov

Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 20, 2018

Primary Completion Date

July 15, 2023

Study Completion Date

July 15, 2023

Conditions

Aplastic AnemiaMyelodysplastic SyndromesFungal Infection

Interventions

DRUG

Posaconazole

"Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks~\*if posaconazole tablet intolerance: posaconazole suspension 200mg tid"

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT03318159 - Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients | Biotech Hunter | Biotech Hunter